MedTrace Logo

Efficacy and Safety of Rotigotine in the Treatment of Patients With Early Stage of Primary Parkinson's Disease

NCT04455555 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 294

Last updated 2020-07-02

No results posted yet for this study

Summary

The efficacy and safety of rotigotine in the treatment of patients with early stage of primary Parkinson's disease

Conditions

Interventions

DRUG

LY03003( the name of rotigotine)

LY03003 (Continuous Dopamine Stimulation) sustained release microspheres / injection once a week 4 weeks followed by 24 weeks until 28 weeks.

OTHER

Placebo

Null sustained release microspheres placebo / injection once a week 4 weeks followed by 24 weeks until 28 weeks.

Sponsors & Collaborators

  • Peking University Third Hospital

    lead OTHER

Principal Investigators

  • Dongsheng Fan, MD.PHD · Peking University Third Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-01
Primary Completion
2019-02-01
Completion
2019-02-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04455555 on ClinicalTrials.gov